Equities

Zydus Lifesciences Ltd

ZYDUSLIFE:NSI

Zydus Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)964.35
  • Today's Change15.45 / 1.63%
  • Shares traded2.66m
  • 1 Year change+50.92%
  • Beta0.4046
Data delayed at least 15 minutes, as of Nov 25 2024 10:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments13,53011,87640,818
Total Receivables, Net60,47350,81639,395
Total Inventory35,97735,79138,982
Prepaid expenses1,0211,016721
Other current assets, total4,0136652,698
Total current assets115,014100,164122,614
Property, plant & equipment, net69,14868,26764,226
Goodwill, net52,66048,04453,646
Intangibles, net26,11010,90511,272
Long term investments9,69611,7799,348
Note receivable - long term1,7592,0011,399
Other long term assets7712,6553,553
Total assets292,808257,564277,954
LIABILITIES
Accounts payable21,26721,25021,378
Accrued expenses12,70213,07711,414
Notes payable/short-term debt7,68610,81033,141
Current portion long-term debt/capital leases1059415,286
Other current liabilities, total11,6599,2297,175
Total current liabilities53,41955,30778,394
Total long term debt2511983,782
Total debt8,04211,94942,209
Deferred income tax4,4651,9441,538
Minority interest22,72121,72520,542
Other liabilities, total13,6573,2323,702
Total liabilities94,51382,406107,958
SHAREHOLDERS EQUITY
Common stock1,0061,0121,024
Additional paid-in capital------
Retained earnings (accumulated deficit)206,341181,441173,133
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(9052)(7295)(4161)
Total equity198,295175,158169,996
Total liabilities & shareholders' equity292,808257,564277,954
Total common shares outstanding1,0061,0121,024
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.